Subscribe to RSS
DOI: 10.1160/TH10-06-0356
The unsialylated subpopulation of recombinant activated factor VII binds to the asialo-glycoprotein receptor (ASGPR) on primary rat hepatocytes
Financial support: For financial support, we wish to thank the Drug Research Academy at the Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark.
Publication History
Received:
08 June 2010
Accepted after major revision:
24 August 2010
Publication Date:
24 November 2017 (online)
Summary
Recombinant activated factor VII (rFVIIa; NovoSeven®) is a heterogeneously glycosylated serine protease used for treatment of haemophiliacs with inhibitors. The drug substance contains a subpopulation consisting of ~20% of rFVIIa molecules which are unsialylated and consists of carbohydrate moieties with terminally exposed galactose and N-acetyl-D-galactosamine (GalNAc). Recently, data from an in situ per-fused liver model showed that a subpopulation of rFVIIa, appearing to be unsialylated rFVIIa, was cleared by the liver, thus suggesting a carbohydrate-moiety mediated mechanism. The parenchymal cells of the liver, hepatocytes, are known to abundantly express functional carbohydrate-specific receptors and in this study we therefore used primary rat hepatocytes to study binding and intracellular fate of rFVIIa at a cellular level. Immunofluorescence microscopy showed that rFVIIa was distributed into distinct intracellular vesicles and electron microscopic autoradiography revealed that radioiodinated rFVIIa distributed only into cytoplasmic free vesicles resembling endosomes and lysosomes. These findings suggest that endocytosis of rFVIIa in hepatocytes could be partly mediated via initial membrane binding to a receptor. Quantitative binding studies showed that the presence of excess unlabelled asialo-orosomucoid, asialo-rFVIIa and GalNAc significantly decreased binding of 125I-rFVIIa. An antibody which specifically binds to the carbohydrate recognition domain of the asialoglycoprotein receptor (ASGPR) significantly decreased binding of asialo-rFVIIa by ~36% and rFVIIa by ~19%. Together our data showed that a receptor-mediated mechanism involving the ASGPR is able to bind a subpopulation of unsialylated rFVIIa, while a hepatic mechanism for binding and clearing sialylated rFVIIa is still unknown.
-
References
- 1 Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-757.
- 2 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
- 3 Franchini M. et al. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-1035.
- 4 Petersen LC. et al. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-826.
- 5 Hagen FS. et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 2412-2416.
- 6 Jurlander B. et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001; 27: 373-384.
- 7 Klausen NK, Kornfelt T. Analysis of the glycoforms of human recombinant factor VIIa by capillary electrophoresis and high-performance liquid chromatography. J Chromatogr A 1995; 718: 195-202.
- 8 Klausen NK. et al. Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry. Mol Biotechnol 1998; 9: 195-204.
- 9 Beeby TL. et al. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats. Thromb Haemost 1993; 70: 465-468.
- 10 Thomsen MK. et al. Pharmacokinetics of recombinant factor VIIa in the rat -a comparison of bio-, immuno- and isotope assays. Thromb Haemost 1993; 70: 458-464.
- 11 Gopalakrishnan R. et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-310.
- 12 Seested T, Nielsen HM, Christensen EI. et al. Cellular and intracellular distribution of recombinant activated factor VII in the rat liver. Thromb Haemost 2010; 103: 860-862.
- 13 Appa RS. et al. Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model. Thromb Haemost 2010; 104: 243-251.
- 14 Smedsrod B. et al. Cell biology of liver endothelial and Kupffer cells. Gut 1994; 35: 1509-1516.
- 15 Seternes T. et al. Scavenger endothelial cells of vertebrates: A nonperipheral leukocyte system for high-capacity elimination of waste macromolecules. Proc Natl Acad Sci USA 2002; 99: 7594-7597.
- 16 Weigel PH, Oka JA. Endocytosis and degradation mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. J Biol Chem 1982; 257: 1201-1207.
- 17 Oka JA. et al. Functional galactosyl receptors on isolated rat hepatocytes are hetero-oligomers. Biochemical and Biophysical Research Communications 1990; 170: 1308-1313.
- 18 Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-554.
- 19 Tolleshaug H. et al. Uptake and degradation of 125I-labelled asialo-fetuin by isolated rat hepatocytes. Biochim Biophys Acta 1977; 499: 73-84.
- 20 Bolt G. et al. Posttranslational N-glycosylation takes place during the normal processing of human coagulation factor VII. Glycobiology 2005; 15: 541-547.
- 21 Nicolaisen EM. et al. Generation of Gla-domainless FVIIa by cathepsin G-mediated cleavage. FEBS Lett 1992; 306: 157-160.
- 22 Hussain MM. et al. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 1999; 19: 141-172.
- 23 Ollivier V. et al. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998; 91: 2698-2703.
- 24 Morrissey JH. et al. Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 1988; 52: 247-261.
- 25 Zeng FY. et al. A Specific Antibody to the Carbohydrate Recognition Domain of the Asialoglycoprotein Receptor RHL1 Subunit Does Not React with RHL2/3 but Blocks Ligand Binding. Biochemical and Biophysical Research Communications 1998; 249: 236-240.
- 26 Regoeczi E. Iodine-labeled plasma proteins. CRC Press Inc.; 1984. pp. 59-61.
- 27 Nielsen R. et al. Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin. J Am Soc Nephrol 1998; 9: 1767-1776.
- 28 Schmitz C. et al. Megalin Deficiency Offers Protection from Renal Aminoglyco-side Accumulation. J Biol Chem 2002; 277: 618-622.
- 29 Christensen EI. et al. Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein. J Histochem Cytochem 1992; 40: 1481-1490.
- 30 Hjortoe G. et al. Factor VIIa binding and internalization in hepatocytes. J Thromb Haemost 2005; 3: 2264-2273.
- 31 Rijken DC. et al. Characterization of the binding of urokinase-type plasminogen activator to the asialoglycoprotein receptor. Thromb Haemost 2002; 88: 83-88.
- 32 Iakhiaev A. et al. Active site blockade of factor VIIa alters its intracellular distribution. J Biol Chem 2001; 276: 45895-45901.
- 33 Weigel PH. Characterization of the asialoglycoprotein receptor on isolated rat hepatocytes. J Biol Chem 1980; 255: 6111-6120.
- 34 Wall DA. et al. The galactose-specific recognition system of mammalian liver: The route of ligand internalization in rat hepatocytes. Cell 1980; 21: 79-93.
- 35 Seested T. et al. Recombinant activated VII (rFVIIa) is reabsorbed in renal proximal tubules and is a ligand to megalin and cubilin. Nephron Exp Nephrol 2011; 117: e82-e92.
- 36 Townsend R, Stahl P. Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. Biochem J 1981; 194: 209-214.
- 37 Narita M. et al. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo. Blood 1998; 91: 555-560.
- 38 Gettins PGW. Serpin Structure, Mechanism, and Function. Chem Rev 2002; 102: 4751-4804.